Ποια είναι η τιμή για Liminal BioSciences Inc. (LMNL)

Η τιμή για Liminal BioSciences Inc. (LMNL) είναι $8.50

Ποια είναι η κεφαλαιοποίηση αγοράς για Liminal BioSciences Inc. (LMNL)

Η κεφαλαιοποίηση αγοράς για Liminal BioSciences Inc. (LMNL) είναι $719.10K

Liminal BioSciences Inc. (LMNL) Τιμή και Κεφαλαιοποίηση Αγοράς

Liminal BioSciences Inc. operates as a clinical-stage biopharmaceutical firm, primarily engaged in creating innovative small molecule drug therapies. The company concentrates on addressing inflammatory, fibrotic, and metabolic diseases, with its operations spanning Canada and the United Kingdom. Its flagship drug candidate, fezagepras (identified as PBI-4050), has successfully advanced through Phase I clinical trials. This agent, along with its related derivatives, is undergoing investigation for potential application in treating idiopathic fibrosis affecting the lungs, liver, heart, or skin, as well as various respiratory conditions. Furthermore, Liminal is advancing antagonist programs, including G-protein coupled receptor 84 (GPR84) and Oxo-eicosanoid receptor 1 (OXER1), both of which are currently in preclinical development. Formerly known as Prometic Life Sciences Inc., the company adopted the name Liminal BioSciences Inc. in October 2019. Established in 1994, its corporate headquarters are located in Laval, Canada.

Η τιμή για LMNL	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$64,651,747 $719.10K	NVDA	$5.470T	+760,608,685.70%
$52,802,260 $719.10K	AAPL	$4.467T	+621,202,959.83%
$49,342,628 $719.10K	GOOG	$4.174T	+580,501,411.11%
$43,736,138 $719.10K	MSFT	$3.700T	+514,542,704.83%
$33,739,275 $719.10K	AMZN	$2.854T	+396,932,551.86%

Η τιμή για LMNL

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$64,651,747 $719.10K